From: Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19
Outcomes | BNT162b2 | ChAdOx1 |
---|---|---|
Number | 536,371 | 774,704 |
Hospitalisation for COVID-19 | ||
 Event (n) | 603 | 1,432 |
 Mean follow-up (months) | 6.74 | 7.41 |
 Incidence ratea, per 1000 person-months | 0.17 | 0.26 |
 Rate difference (95%CI) a, per 1000 person-months | -0.09 (-0.13, -0.05) | 0.00 (ref) |
 Hazard ratio (95% CI) a | 0.65 (0.57, 0.74) | 1.00 (ref) |
Death from COVID-19 | ||
 Event (n) | 42 | 112 |
 Mean follow-up (months) | 6.74 | 7.41 |
 Incidence ratea, per 1000 person-months | 0.018 | 0.022 |
 Rate difference (95%CI) a, per 1000 person-months | -0.005 (-0.016, 0.006) | 0.00 (ref) |
 Hazard ratio (95% CI) a | 0.66 (0.42, 1.04) | 1.00 (ref) |